Not all data is equally valuable. Strategic medical insights—those that inform strategy and improve patient outcomes—are essential. In a recent article in Med Ad News (PharmaLive), Susan Giacalone explores how Medical Science Liaisons (MSLs) are redefining their value in the pharmaceutical industry. While MSLs have always been trusted partners to healthcare professionals, today’s environment demands more than trust—it requires measurable, personalized scientific engagement.
The integration of AI-powered tools and modular content systems is transforming the way MSLs interact with healthcare providers. Technology is allowing MSLs to process complex data, generate actionable insights and deliver tailored scientific content that demonstrates clear value to both internal stakeholders and clinicians.
Read the full article in Med Ad News (PharmaLive) for a deeper look at these evolving trends.
Author Team
EVERSANA employs a team of over 6000 professionals across 20+ locations around the world. From industry-leading patient service and adherence support to global pricing and revenue management, our team informs the strategies that matter…